My point on when they bought is that those who wanted to make money in their investment here. Though these days cutting losses is probably appealing enough :)
I don't think BMRN is paying too much basically they will fund its development as long as the trial is on-going for a 50% share. That doesn't seem to pricey to me. There is no way the trial would continue otherwise :). OK if the drug is approved they'll have some milestones but nothing seems to outrageous if peak sales are say 500-600+ million and I think they said patents go out to 2018 (plus they have orphan status). I've been thinking what type of deal La Jolla would have gotten a couple years ago (and went for) and I am guessing EU rights only and say 50 million up-front and 75-100 million on approval with perhaps some other sales milestones and say a 10-15% royalty. Here they gave up basically 50% of all markets (ok they still have asia/australia).
If the drug works do you have any sense for how much they could charge? Aselage said that market research they have done indicated monthly dosing would be better accepted. Appreciate any thought you may have on this.
Market Data 
Markets 
AI
